Zulfiqar Ali
Psychiatry · Indianapolis, INNPI 1336276823
Payments from drug & device makers
Across 269 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$729
- Lundbeck LLC$531
- Alkermes, Inc.$475
- Vanda Pharmaceuticals Inc.$389
- Neurocrine Biosciences, Inc.$342
- Teva Pharmaceuticals USA, Inc.$285
- plus $1K from 11 others
What the payments were for
- Food & beverage$4,07099%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $729 |
| Lundbeck LLC | 32 | $531 |
| Alkermes, Inc. | 27 | $475 |
| Vanda Pharmaceuticals Inc. | 22 | $389 |
| Neurocrine Biosciences, Inc. | 25 | $342 |
| Teva Pharmaceuticals USA, Inc. | 16 | $285 |
| Otsuka America Pharmaceutical, Inc. | 13 | $261 |
| Johnson & Johnson | 17 | $234 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $212 |
| Indivior Inc. | 9 | $150 |
| Supernus Pharmaceuticals, Inc. | 8 | $133 |
| Ironshore Pharmaceuticals Inc. | 8 | $125 |
| Adlon Therapeutics L.p. | 5 | $82 |
| Eisai Inc. | 6 | $80 |
| Corium, LLC | 3 | $46 |
| Sunovion Pharmaceuticals Inc. | 3 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
How this compares
$4,117 in reported general payments places this provider in the 80th percentile of 514 psychiatry providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 22 | $73,582 |
| Abilify MaintenaAripiprazole | 15 | $42,451 |
| RexultiBrexpiprazole | 15 | $26,556 |
| TrintellixVortioxetine Hydrobromide | 39 | $19,542 |
| Lurasidone Hcl | 56 | $15,721 |
| Paliperidone ErPaliperidone | 41 | $15,278 |
| Olanzapine | 75 | $11,250 |
| Aripiprazole | 48 | $7,700 |
| Divalproex Sodium ErDivalproex Sodium | 59 | $5,483 |
| Clozapine | 80 | $3,798 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 19 | $2,990 |
| Trazodone Hcl | 154 | $2,717 |
| Atomoxetine Hcl | 23 | $2,469 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 26 | $2,193 |
| Quetiapine Fumarate | 83 | $1,967 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $234 | $73,58222 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $261 | $69,00730 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $15 | $19,54239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Indianapolis
- Anantha ShekharIndianapolis$433K
- Leslie HulvershornIndianapolis$159K
- Charles BeasleyIndianapolis$129K
- Alan BreierIndianapolis$114K
- John NurnbergerIndianapolis$104K
- Susan ConroyIndianapolis$73K
- Dmitry ArbuckIndianapolis$40K
- Michael FrancisIndianapolis$26K
- Albert AllenIndianapolis$24K
- Jerad DaltonIndianapolis$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.